The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
They will commercialize molnupiravir in the international markets
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
This is the company’s first partnership arrangement in China
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Subscribe To Our Newsletter & Stay Updated
